The executive order will open the door for more research into the psychedelic drug ibogaine, sources told CBS News earlier ...
The order instructs the FDA to expedite review of drugs such as ibogaine, a drug that veterans' groups have said can help ...
President Trump has signed an executive order to make certain psychedelic drugs more available to treat mental health ...
By the authority vested in me as President by the Constitution and the laws of the United States of America, it is hereby ordered: Section 1. Purpose and ...
The numbers are the first to quantify the effect of the Trump administration’s shutdown and restarting of a program that has ...
New Haven-based Trevi Therapeutics Inc. disclosed it is seeking to raise $150 million through a public stock offering to ...
This press release shall not constitute an offer to sell, or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which ...
Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy ...
Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) ("Reviva," the "Company" "we" or "us"), a late-stage pharmaceutical company developing therapies ...
Deupirfenidone slowed the progression of lung disease over 26 weeks in patients with idiopathic pulmonary fibrosis in a clinical trial.
Haisco Pharmaceutical Group Co. Ltd. has disclosed new lysophosphatidic acid receptor 1 (LPAR1; EDG2) antagonists reported to be useful for the treatment of idiopathic pulmonary fibrosis.
University of Colorado Denver Biomedical Engineering Associate Professor Chelsea Magin is developing a lung model to help ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results